A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
Kim HS, Park SY, Park CY, Kim YT, Kim BJ, Song YJ, Kim BG, Kim YB, Cho CH, Kim JH, Song YS.
Kim HS, et al. Among authors: kim bg, kim bj, kim yb, kim yt, kim jh.
Br J Cancer. 2021 Jan;124(2):375-382. doi: 10.1038/s41416-020-01098-8. Epub 2020 Sep 30.
Br J Cancer. 2021.
PMID: 32994466
Free PMC article.
Clinical Trial.